NCT04155541Completed
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Special Investigation for Vizimpro Tablets
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 5 Nov 2019
- Start date
- 24 Jan 2020
- Primary completion date
- 25 Apr 2025
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT04155541
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 24 Jan 2020 to the primary completion date, 25 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Exclusion criteria is not provided in this study
Who the study is looking for
- patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received VIZIMPRO(dacomitinib hydrate)
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Japan Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.